Literature DB >> 11596878

Anthrax toxin.

R Bhatnagar1, S Batra.   

Abstract

Anthrax is primarily a disease of herbivores caused by gram-positive, aerobic, spore-forming Bacillus anthracis. Humans are accidental hosts through the food of animal origin and animal products. Anthrax is prevelant in most parts of the globe, and cases of anthrax have been reported from almost every country. Three forms of the disease have been recognized: cutaneous (through skin), gastrointestinal (through alimentary tract), and pulmonary (by inhalation of spores). The major virulence factors of Bacillus anthracis are a poly-D glutamic acid capsule and a three-component protein exotoxin. The genes coding for the toxin and the enzymes responsible for capsule production are carried on plasmid pXO1 and pXO2, respectively. The three proteins of the exotoxin are protective antigen (PA, 83 kDa), lethal factor (LF, 90 kDa), and edema factor (EF, 89 kDa). The toxins follow the A-B model with PA being the B moeity and LF/EF, the alternative A moeities. LF and EF are individually nontoxic, but in combination with PA form two toxins causing different pathogenic responses in animals and cultured cells. PA + LF forms the lethal toxin and PA + EF forms the edema toxin. During the process of intoxication, PA binds to the cell surface receptor and is cleaved at the sequence RKKR (167) by cell surface proteases such as furin generating a cell-bound, C-terminal 63 kDa protein (PA63). PA63 possesses a binding site to which LF or EF bind with high affinity. The complex is then internalized by receptor-mediated endocytosis. Acidification of the vesicle leads to instertion of PA63 into the endosomal membrane and translocation of LF/EF across the bilayer into the cytosol where they exert their toxic effects. EF has a calcium- and calmodulin-dependent adenylate cyclase activity. Recent reports indicate that LF is a protease that cleaves the amino terminus of mitogen-activated protein kinase kinases 1 and 2 (MAPKK1 and 2), and this cleavage inactivates MAPKK1 and thus inhibits the mitogen-activated protein kinase signal transduction pathway. We describe in detail the studies so far done on unraveling the molecular mechanisms of pathogenesis of Bacillus anthracis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596878     DOI: 10.1080/20014091096738

Source DB:  PubMed          Journal:  Crit Rev Microbiol        ISSN: 1040-841X            Impact factor:   7.624


  22 in total

1.  Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection.

Authors:  Christopher K Cote; Nico Van Rooijen; Susan L Welkos
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Murine macrophage transcriptional responses to Bacillus anthracis infection and intoxication.

Authors:  Nicholas H Bergman; Karla D Passalacqua; Renee Gaspard; Lynne M Shetron-Rama; John Quackenbush; Philip C Hanna
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  Anthrax lethal factor represses glucocorticoid and progesterone receptor activity.

Authors:  Jeanette I Webster; Leonardo H Tonelli; Mahtab Moayeri; S Stoney Simons; Stephen H Leppla; Esther M Sternberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-30       Impact factor: 11.205

4.  Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility.

Authors:  C Rick Lyons; Julie Lovchik; Julie Hutt; Mary F Lipscomb; Eugenia Wang; Sara Heninger; Lucy Berliba; Kristin Garrison
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

5.  Anthrax lethal toxin inhibits translation of hypoxia-inducible factor 1α and causes decreased tolerance to hypoxic stress.

Authors:  Weiming Ouyang; Chikako Torigoe; Hui Fang; Tao Xie; David M Frucht
Journal:  J Biol Chem       Date:  2013-12-23       Impact factor: 5.157

6.  Bacillus anthracis lethal toxin represses MMTV promoter activity through transcription factors.

Authors:  Zhigang Kang; Jeanette I Webster Marketon; Antoinette Johnson; Esther M Sternberg
Journal:  J Mol Biol       Date:  2009-04-21       Impact factor: 5.469

7.  Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.

Authors:  Wendy A Keitel; John J Treanor; Hana M El Sahly; Thomas G Evans; Scott Kopper; Vanessa Whitlow; Cheryl Selinsky; David C Kaslow; Alain Rolland; Larry R Smith; Peggy A Lalor
Journal:  Hum Vaccin       Date:  2009-08-14

8.  A novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system.

Authors:  Yu-Tsueng Liu; Shwu-Bin Lin; Cheng-Po Huang; Chun-Ming Huang
Journal:  Protein Expr Purif       Date:  2007-09-14       Impact factor: 1.650

9.  Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed.

Authors:  Donald Reason; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Infect Immun       Date:  2009-02-17       Impact factor: 3.441

10.  In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.

Authors:  Herman F Staats; S Munir Alam; Richard M Scearce; Shaun M Kirwan; Julia Xianzhi Zhang; William M Gwinn; Barton F Haynes
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.